1-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid | 1193381-98-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 1-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid
• 英文别名: 1-(5-Trifluoromethyl-1H-benzoimidazol-2-yl)-1H-；1-[6-(trifluoromethyl)-1H-benzimidazol-2-yl]pyrazole-4-carboxylic acid
• CAS: 1193381-98-4
• 化学式: C₁₂H₇F₃N₄O₂
• 分子量: 296.208
• InChiKey: FEOYPRRUCRESLL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  83.8
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• [EN] BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS<br/>[FR] BENZOIMIDAZOLES COMME INHIBITEURS DE LA PROLYL HYDROXYLASE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2009134750A1

  公开（公告）日：2009-11-05

  The present invention is directed to benzoimidazole compounds of the formula (1) and enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts thereof. Compounds of the present invention are useful in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions modulated by prolyl hydroxylase activity.

  本发明涉及公式（1）的苯并咪唑化合物及其对映体、二对映体、消旋体和药学上可接受的盐。本发明的化合物在制药组合物和治疗由脯氨酸羟化酶活性调节的疾病状态、紊乱和条件的方法中是有用的。
• BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS
  申请人：Hocutt Frances Meredith

  公开号：US20110046132A1

  公开（公告）日：2011-02-24

  The present invention is directed to benzoimidazole compounds of the formula (1) and enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts thereof. Compounds of the present invention are useful in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions modulated by prolyl hydroxylase activity.

  本发明涉及公式（1）的苯并咪唑化合物及其对映体、二对映异构体、外消旋体和药学上可接受的盐。本发明化合物在制药组合物和治疗疾病状态、紊乱和通过脯氨酸羟化酶活性调节的疾病条件的方法中是有用的。
• Benzoimidazoles as prolyl hydroxylase inhibitors
  申请人：Janssen Pharmaceutica NV

  公开号：US20150284335A1

  公开（公告）日：2015-10-08

  Certain Benzoimidazole compounds are described, which are useful as prolyl hydroxylase inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by prolyl hydroxylase activity. Thus, the compounds may be administered to treat, e.g., Anemia, vascular disorders, metabolic disorders, and wound healing.

  本文描述了某些苯并咪唑化合物，这些化合物可用作丙氨酸羟化酶抑制剂。这些化合物可用于制备药物组合物和治疗由丙氨酸羟化酶活性介导的疾病状态、紊乱和情况的方法。因此，这些化合物可用于治疗贫血、血管紊乱、代谢紊乱和伤口愈合等疾病。
• US20140256722A1
  申请人：——

  公开号：US20140256722A1

  公开（公告）日：2014-09-11
• US8759345B2
  申请人：——

  公开号：US8759345B2

  公开（公告）日：2014-06-24